- Home
- MIRM vs FLR Comparison
MIRM vs FLR Comparison
Compare MIRM & FLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIRM | FLR |
|---|---|---|
| Founded | 2018 | 1912 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Military/Government/Technical |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 6.6B |
| IPO Year | 2019 | 2006 |
Fundamental Metrics
Financial Performance| Metric | MIRM | FLR |
|---|---|---|
| Price | $107.51 | $47.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 6 |
| Target Price | ★ $119.85 | $53.50 |
| AVG Volume (30 Days) | 595.3K | ★ 1.9M |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 74.59 | N/A |
| EPS | N/A | ★ 1.08 |
| Revenue | $19,138,000.00 | ★ $15,503,000,000.00 |
| Revenue This Year | $26.22 | $6.56 |
| Revenue Next Year | $22.04 | $7.10 |
| P/E Ratio | ★ N/A | $45.70 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $50.25 | $37.62 |
| 52 Week High | $130.00 | $57.00 |
Technical Indicators
Market Signals| Indicator | MIRM | FLR |
|---|---|---|
| Relative Strength Index (RSI) | 40.82 | 39.07 |
| Support Level | $87.93 | $46.87 |
| Resistance Level | $114.99 | $48.90 |
| Average True Range (ATR) | 4.52 | 1.73 |
| MACD | -1.87 | -0.27 |
| Stochastic Oscillator | 2.05 | 5.78 |
Price Performance
Historical ComparisonAbout MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
About FLR Fluor Corporation
Fluor is one of the largest global providers of engineering, procurement, construction, fabrication, operations, and maintenance services. It serves a wide range of end markets, including oil and gas, chemicals, mining, metals, and transportation. The company's business is organized into three core segments: urban solutions, mission solutions, and energy solutions. Fluor generated $15.5 billion in revenue in 2025.